

美国医学写作协会、欧洲医学写作协会和 国际医学出版专业人士协会联合立场声明： 专业医学撰稿人的角色

发布时间：2017年1月

引言

美国医学写作协会（the American Medical Writers Association, 简称 AMWA）、欧洲医学写作协会（the European Medical Writers Association, 简称 EMWA）和国际医学出版专业人士协会（the International Society for Medical Publication Professionals, 简称 ISMPP）联合发布了专业医学撰稿人在制定和发表医学科研论著时应遵守的行为规范和责任义务，规范其如下行为：

- 在具有同行评审的期刊上发表文章及补充性内容（如视频摘要）
- 在科学大会上发表摘要、壁报和做口头报告。

本联合立场声明与其他医学研究和医学写作国际组织的最新指导原则一脉相承。¹⁻¹³

专业医学撰稿人的职责

专业的医学写作支持能帮助作者和申办方在同行评审期刊上及科学大会上发表他们的研究成果，且发布行为符合伦理规范，¹⁴内容准确无误，^{15,16}发表及时有效¹⁷，其终极目标是促进病患护理。专业医学撰稿人应充分理解发表医学研究报告的伦理道德规范。^{18,19}当协助作者发表公司申办的研究成果时，他们必须：

- 遵守医学研究出版规范（GPP3）指导原则，遵从国际医学期刊编辑委员会（International Committee of Medical Journal Editors, 简称 ICMJE）的推荐规范建议^{1,2}
- 参考相应的医学报告指导原则（例如，报告平行对照随机临床实验研究指南（Consolidated Standards of Reporting Trials, 简称 CONSORT）²⁰及其他 EQUATOR 网络（www.EQUATOR-network.org）²¹整理出来的报告指南）
- 确保作者和申办方充分理解这些指导原则提出的责任义务和行为规范^{1,2,20,21}
- 获取最新的医学沟通出版伦理和最佳实践，保持与时俱进。

与专业医学撰稿人合作的作者的责任和义务

选择和专业医学撰稿人合作来完成文章原稿或科学大会发言材料的作者们必须：

- 确保他们自己作为作者对所有的相关信息（例如，研究方案、统计分析计划、统计分析和临床研究报告）拥有完全查阅权
- 在写作开始前和内容制定过程中均提供实质性知识性投入或贡献
- 确保最终的成文能充分反映全体作者的观点，且获得全体作者的核准
- 确认最终选择的目标期刊或科学大会是恰当合适的
- 披露医学写作支持细节，包括支持的性质、撰稿人姓名、最高相关资格资质（例如，学位或专业证书）、该专业医学撰稿人所属单位，并且披露该医学写作支持赞助资金的来源（参见方框内容）
- 把所有满足国际医学期刊编辑委员会所指定的署名标准的贡献人（包括专业医学撰稿人）列为共同作者之一。¹

专业医学写作支持详情披露声明模板

“在此作者感谢[国家、城市、公司]的[姓名和资格]所提供的医学写作支持/编辑支持[酌情详细说明或扩展]，该支持由[国家、城市、资助公司名称]所提供，符合医学研究出版规范（GPP3）指导原则（<http://www.ismpp.org/gpp3>）。”

References

1. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. <http://www.icmje.org/icmje-recommendations.pdf>. Published December 2016. Accessed December 28, 2016.
2. Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. *Ann Intern Med*. 2015;163:461–464.
3. Clark J, Gonzalez J, Mansi B, et al. Enhancing transparency and efficiency in reporting industry-sponsored clinical research: report from the Medical Publishing Insights and Practices initiative. *Int J Clin Pract*. 2010;64:1028–1033.
4. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. <http://www.wma.net/en/30publications/10policies/b3/>. Updated October 2013. Accessed December 20, 2016.
5. World Health Organization. Statement on public disclosure of clinical trial results. http://www.who.int/ictip/results/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1. Published 2015. Accessed November 26, 2016.
6. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Japanese Pharmaceutical Manufacturers Association (JPMA), Pharmaceutical Research and Manufacturers of America (PhRMA). Joint position on the publication of clinical trial results in the scientific literature. http://www.efpia.eu/uploads/Modules/Documents/20100610_joint_position_publication_10jun2010.pdf. Published 2010. Accessed November 25, 2016.
7. Pharmaceutical Research and Manufacturers of America. Principles on conduct of clinical trials: communication of clinical trial results. http://www.phrma.org/sites/default/files/pdf/042009_clinical_trial_principles_final_0.pdf. Updated December 2014. Accessed December 20, 2016.
8. Hamilton CW, Royer MG. AMWA position statement on the contributions of medical writers to scientific publications. *AMWA J*. 2003;18:13–16.
9. American Medical Writers Association. Code of ethics. http://www.amwa.org/amwa_ethics. Updated June 2008. Accessed September 30, 2016.
10. Jacobs A, Wager E. European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. *Curr Med Res Opin*. 2005;21:317–322.
11. Norris R, Bowman A, Fagan JM, et al. International Society for Medical Publication Professionals (ISMPP) position statement: the role of the professional medical writer. *Curr Med Res Opin*. 2007;23:1837–1840.
12. International Society for Medical Publication Professionals. Position statement: the role of the professional medical writer. http://www.ismpp.org/assets/docs/Inititives/advocacy/ismpp_ghost_writing_vs_professional_medical_writing_oct_2011.pdf. Published 2011. Accessed September 30, 2016.
13. International Society for Medical Publication Professionals. Code of ethics. <http://www.ismpp.org/ethics>. Updated November 1, 2016. Accessed November 25, 2016.
14. Woolley K, Lew RA, Stretton S, et al. Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study. *Curr Med Res Opin*. 2011;27:1175–1182.
15. Jacobs A. Adherence to the CONSORT guideline in papers written by professional medical writers. *Write Stuff*. 2010;19:196–199.
16. Gattrell WT, Hopewell S, Young K, et al. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. *BMJ Open*. 2016;6:e010329.
17. Shah S, Nair S, Patil A, et al. Role of medical publication professional in timely dissemination and transparent reporting of clinical data. *Curr Med Res Opin*. 2016;32(Suppl 1):S12.
18. Wager E, Woolley K, Adshead V, et al. Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey. *BMJ Open*. 2014;4:e004780.
19. Marusic A, Hren D, Mansi B, et al. Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications. *BMC Med*. 2014;12:197.
20. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
21. Reporting guidelines for main study types. EQUATOR Network Web site. <http://www.equator-network.org/>. Accessed December 20, 2016.